Epidemiological, clinical and therapeutic features of hepatocellular carcinoma in cirrhotic patients

Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008; 14:4300-8.

Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001; 35:421-30.

Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42:1208-36.

Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53:1020-2.

Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: theBCLC staging classification. Semin Liver Dis 1999; 19:329-38.

Mac Glynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2005; 19:3-23.

Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.

Velazquez RF, Rodriguez M, Navascues CA, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology2003; 37: 520-27.

Registre des cancers Nord-Tunisie 1993-2003. Institut national de la santé publique. Ministère de la santé publique.

Ouakaa-Kchaou A, Belhadj N, Abdelli N, et al. Survival in cirrhosis. Tunis Med 2010; 88:804-8.

Triki H, Said N, Ben Salah A, et al. Seroepidemiology of hepatitis B, C and delta viruses in Tunisia. Trans R Soc Trop Med Hyg 1997, 91:11-4.

Mejri S, Salah AB, Triki H, Alaya NB, Djebbi A, Dellagi K: Contrasting patterns of hepatitis C virus infection in two regions from Tunisia. J Med Virol 2005, 76:185-93.

Forner A, Reig M, Bruix J. Alpha-fetoprotein for hepatocellular carcinoma diagnosis: the demise of a brilliant star. Gastroenterology 2009; 137:26-9.

Sangiovanni A, Manini MA, Iavarone M, et al. The diagnostic and economic impact of contrast imaging technique in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010; 59:570-1.

Blanc JF, Bioulac-Sage P, Trillaud H, Zucman-Rossi J, Balabaud C. Les lésions précancéreuses sur foie cirrhotique et non cirrhotique. Gastroenterol Clin Biol 2004; 28:158-70.

Hefaiedh R, Elloumi H, Ouakaa A, M, et al. Management of the hepatocellular carcinoma. Tunis Med 2009; 87:721-5.

Rampone B, Schiavone B, Martino A, Viviano C, Confuorto G. Current management strategy of hepatocellular carcinoma. World J Gastroenterol 2009; 15: 3210-6.

Bartlett A, Heaton N. Hepatocellular carcinoma: defining the place of surgery in an era of organ shortage. World J Gastroenterol 2008; 14: 4445-53.

Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009;49: 453-9.

Yamazaki S, Takayama T. Surgical treatment of hepatocellular carcinoma: evidence based outcomes. World J Gastroenterol 2008; 14:685-92.

Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival.Hepatology 2003; 37:429-42.

Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.